Spotlight on rituximab as a new therapeutic option for dermatomyositis and thrombotic thrombocytopenic purpura.
This month's Spotlight on... will focus on rituximab, a chimeric monoclonal antibody approved for the treatment of non-Hodgkin's lymphoma, but it has been revealed as a promising therapeutic approach for two serious conditions: dermatomyositis and refractory thrombotic thrombocytopenic purpura.